Detailed Narrative
Q1 FY27 Financial Performance Overview
Max Healthcare Institute Limited reported a strong Q1 FY27, with revenue growing 16% year-on-year to ₹2,982 crore and 12% quarter-on-quarter. Operating EBITDA increased 15% year-on-year and 3% quarter-on-quarter, reaching ₹704 crore. The network maintained an average occupancy of over 75% despite a 13% year-on-year increase in operational bed capacity, while Average Revenue Per Occupied Bed (ARPOB) grew 5% year-on-year to ₹81,900. Profit after Tax (PAT) for the quarter stood at ₹357 crore, a 3.47% increase from Q1 FY26.
Strategic Capacity Expansion Initiatives
The company is actively pursuing its capacity expansion plans across multiple locations. At Max Smart, 50% of the 400-bed brownfield tower is now operational, with the remaining 50% expected to be handed over in the current quarter, and opened beds are already at 80% occupancy. The board has approved a significant capital expenditure of ₹425 crore for a new 202-bed brownfield tower at Max Vaishali, slated for commissioning before FY30. Additionally, phased commissioning of 500 beds at Sector 56 Gurgaon is expected by the end of this year, and 100 additional beds at Max Lucknow will be commissioned over the next two quarters.
Integration of Recent Acquisitions and Turnaround Strategy
The integration of Max Bhubaneswar, acquired for ₹153 crore, is progressing as planned, contributing ₹19 crore in revenue and ₹2 crore in EBITDA in Q1 FY27 post-acquisition, with an occupancy of 50% and ARPOB of ₹35,000. The company's focus for the next 12 months is on integrating operations, renovating infrastructure, upgrading technology, and enhancing clinical programs to improve the hospital's performance. The SPV for the Pune greenfield project has also been acquired, making it a subsidiary of the company.
Entry into Medical Education Business
Max Healthcare has received in-principle board approval to enter the medical education business, projecting a Return on Capital Employed (ROCE) of over 25%. This strategic move is facilitated by recent changes in National Medical Commission guidelines allowing for-profit companies to establish medical colleges. The company estimates a spend of approximately ₹300 crore for a 150-seat medical college, which it intends to fund entirely through internal accruals, with commercial operations expected to commence over the next few years.
Challenges in Oncology Segment and Free Cash Flow
The oncology segment faced headwinds, with its share of in-patient revenues dropping to 22% from 26% in Q1 FY26, primarily due to the discontinuation of select high-value chemotherapy drugs for institutional patients. Management anticipates normalization of oncology revenue from Q3 FY27. Furthermore, free cash flow growth was significantly lower at 3% compared to EBITDA growth of 15%, mainly attributed to an increase in Accounts Receivable, with Days Sales Outstanding (DSO) rising from 87 to 95 days, and a higher effective tax rate.
Digital Growth and Ancillary Business Performance
Digital initiatives continue to drive growth, with digital revenue from online marketing activities, web-based appointments, and digital lead management reaching ₹941 crore, accounting for approximately 32% of overall revenue. Website traffic saw a substantial increase of 41% year-on-year, crossing 97 lakh sessions. The company's strategic business units also performed well, with Max@Home reporting ₹78 crore in revenue (32% YoY growth) and Max Lab recording ₹58 crore in revenue (20% YoY growth).
Net Debt Position and Capital Allocation Flexibility
Net debt for the network increased to ₹2,384 crore at the end of Q1 FY27 from ₹1,908 crore at March 2026, primarily due to the Kalinga acquisition and the put option liability for the Pune project. Despite this increase, the net debt-to-EBITDA ratio remained below 1. Management indicated a willingness to increase the net debt-to-EBITDA ratio up to 2.5x for future strategic acquisitions, highlighting flexibility in capital allocation for growth.